Physician profile
Robert J Esper
NPI 1790767457
$9,966.60
in general payments reported to CMS, 2019-2025
39 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $1,551 · 2021: $1,954 · 2022: $1,388 · 2023: $1,355 · 2024: $1,165 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,664.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,108.82 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,106.33 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Pfizer INC. | $1,099.33 | 2019-2025 | |
| Novo Nordisk INC | $777.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $657.20 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $640.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $587.89 | 2019-2024 | Spravato |
| Exact Sciences Corporation | $548.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $545.42 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $444.30 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $401.15 | 2019-2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.04 | 2019-2024 | Xifaxan |
| Amgen INC. | $230.98 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $166.34 | 2019-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $165.88 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Esper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.